VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy

Current Oncology Reports

Volumn 11, Issue 2, 2009, Pages 94-101

  Cowey, C Lance ^b   Rathmell, W Kimryn ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VON HIPPEL LINDAU PROTEIN;

CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; DRUG EFFICACY; EPIGENETICS; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; KIDNEY CARCINOMA; MOLECULAR BIOLOGY; MUTATIONAL ANALYSIS; NEPHRECTOMY; NONHUMAN; PHARMACOGENETICS; PROGNOSIS; PROMOTER REGION; PROTEIN METHYLATION; REVIEW; SIGNAL TRANSDUCTION;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MUTATION; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 60349101704     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-009-0015-5     Document Type: Review

References (46)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol 2000, 163:408-417.
3. Bukowski RM: Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 2001, 19:148-154.
4. Motzer RJ, Mazumdar M, Bacik J, et al.: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17: 2530-2540.
5. Cowey C, Rathmell WK: Using molecular biology to develop drugs for renal cell carcinoma. Expert Opin Drug Discov 2008, 3:311-327.
6. Kaelin WG Jr: The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007, 13(2 Pt 2): 680s-684s.
7. Motzer RJ, Hutson TE, Tomczak P, et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
8. Escudier B, Eisen T, Stadler WM, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
9. Hudes G, Carducci M, Tomczak P, et al.: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
10. Lonser RR, Glenn GM, Walther M, et al.: Von Hippel-Lindau disease. Lancet 2003, 361:2059-2067.
11. Latif F, Tory K, Gnarra J, et al.: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260:1317-1320.
12. Iliopoulos O, Levy AP, Jiang C, et al.: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996, 93:10595-10599.
13. Iwai K, Yamanaka K, Kamura T, et al.: Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci U S A 1999, 96:12436-12441.
14. Maxwell PH, Wiesener MS, Chang GW, et al.: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.
15. Wiesener MS, Munchenhagen PM, Berger I, et al.: Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 2001, 61:5215-5222.
16. Iliopoulos O, Kibel A, Gray S, et al.: Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1995, 1:822-826.
17. Chen F, Kishida T, Duh FM, et al.: Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res 1995, 55:4804-4807.
18. Zbar B, Kishida T, Chen F, et al.: Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 1996, 8:348-357.
19. Friedrich CA: Genotype-phenotype correlation in von Hippel-Lindau syndrome. Hum Mol Genet 2001, 10:763-767.
20. Hacker KE, Lee CM, Rathmell WK: VHL type 2B mutations retain VBC form and function. PLoS ONE 2008, 3:e3801.
21. Li L, Zhang L, Zhang X, et al.: Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol Cell Biol 2007, 27:5381-5392.
22. Foster K, Prowse A, van den Berg A, et al.: Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994, 3:2169-2173.
23. Gnarra JR, Tory K, Weng Y, et al.: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994, 7:85-90.
24. Shuin T, Kondo K, Torigoe S, et al.: Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994, 54:2852-2855.
25. Nickerson ML, Jaeger E, Shi Y, et al.: Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008, 14:4726-4734.
26. Herman JG, Latif F, Weng Y, et al.: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994, 91:9700-9704.
27. Clifford SC, Prowse AH, Affara NA, et al.: Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 1998, 22:200-209.
28. Dulaimi E, Ibanez de Caceres I, Uzzo RG, et al.: Promoter hypermethylation profile of kidney cancer. Clin Cancer Res 2004, 10(12 Pt 1):3972-3979.
29. Brauch H, Weirich G, Brieger J, et al.: VHL alterations in human clear cell renal cell carcinoma: Association with advanced tumor stage and a novel hot spot mutation. Cancer Res 2000, 60:1942-1948.
30. Schraml P, Struckmann K, Hatz F, et al.: VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002, 196:186-193.
31. Patard JJ, Fergelot P, Karakiewicz PI, et al.: Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 2008, 123:395-400.
32. Yao M, Yoshida M, Kishida T, et al.: VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002, 94:1569-1575.
33. Kondo K, Yao M, Yoshida M, et al.: Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002, 34:58-68.
34. Smits KM, Schouten LJ, van Dijk BA, et al.: Genetic and epigenetic alterations in the von hippel-lindau gene: The influence on renal cancer prognosis. Clin Cancer Res 2008, 14:782-787.
35. Gimenez-Bachs JM, Salinas-Sanchez AS, Sanchez-Sanchez F, et al.: Determination of vhl gene mutations in sporadic renal cell carcinoma. Eur Urol 2006, 49: 1051-1057.
36. Upton MP, Parker RA, Youmans A, et al.: Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 2005, 28:488-495.
37. Kim JH, Jung CW, Cho YH, et al.: Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep 2005, 13:859-864.
38. Choueiri TK, Vaziri SA, Jaeger E, et al.: Von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008, 180:860-865; discussion 865-866.
39. Rini BI, Jaeger E, Weinberg V, et al.: Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: Impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int 2006, 98:756-762.
40. Gad S, Sultan-Amar V, Meric JB, et al.: Somatic von Hippel-Lindau (VHL) gene analysis and clinical outcome under antiangiogenic treatment in metastatic renal cell carcinoma: Preliminary results. Targeted Oncol 2007, 2:3-6.
41. Cho D, Signoretti S, Regan M, et al.: The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 2007, 13(2 Pt 2):758s-763s.
42. Lynch TJ, Bell DW, Sordella R, et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
43. Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology 2005, 69(Suppl 3):4-10.
44. Miller K, Wang M, Gralow J, et al.: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
45. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
46. Llovet JM, Ricci S, Mazzaferro V, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.